Status: Recruiting
CS-121 APOC3 Base Editing in Children and Adolescents With Hyperchylomicronemia
This is a Prospective, Single-center, Open-label, Single-arm Clinical Study to Evaluate the Safety and Efficacy of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3, in Children and Adolescents (4-18 years) With Hyperchylomicronemia
Participants needed: 15
Trial details
Phase: Early Phase 1Age: 4-18Biological sex: AllType: InterventionalSponsor: Shanghai Jiao Tong University School of MedicineUpdated: Jan 28, 2026Locations: 1
Eligibility criteria
Male or female participants aged 4 years ≤ age < 18 years. [+5]
Currently participating in other interventional clinical studies, or having an i... [+15]